文献速递核素与放射性配体治疗肿瘤 PET/CT

动物模型中CD38靶向α与β核素治疗播散性多发性骨髓瘤的比较

Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model.
PubMed 文献 · J Nucl Med · 2020-10-30

该临床前研究在播散性多发性骨髓瘤动物模型中,比较了177Lu(β发射体)与225Ac(α发射体)标记的DOTA-daratumumab的疗效与毒性。结果显示,225Ac-DOTA-daratumumab在延迟肿瘤生长和降低全身毒性方面优于177Lu标记物,且数学模型证实靶向α治疗达到了最大生物剂量。

要点

  • 225Ac标记的CD38靶向α治疗在延迟肿瘤生长和降低全身毒性方面优于177Lu标记的β治疗。
  • 177Lu在11.1 MBq时虽根除肿瘤,但因全身毒性对生存无改善。
  • 225Ac在0.925、1.85和3.7 kBq时呈剂量依赖性延长生存并显著延迟肿瘤生长。

核心结论

  • 靶向α治疗(225Ac-DOTA-daratumumab)在延迟肿瘤生长和降低全身毒性方面优于靶向β治疗(177Lu-DOTA-daratumumab),数学模型证实靶向α治疗达到了最大生物剂量。

研究设计与样本

  • 在播散性多发性骨髓瘤临床前模型中,比较了使用放射性标记DOTA-daratumumab的β发射体与α发射体放射免疫治疗的潜在疗效,并探索多个剂量水平以寻找疗效最高且毒性最低的剂量。

主要发现

  • 在177Lu-DOTA-daratumumab剂量-反应研究中,最低测试剂量1.85 MBq将生存期从37天延长至47天但未延迟肿瘤生长。
  • 177Lu剂量3.7和7.4 MBq分别将生存期延长至55天和58天,引起小的等效肿瘤生长延迟,随后肿瘤再生长。
  • 177Lu更高剂量11.1 MBq根除了肿瘤,但因全身毒性对生存期与未治疗对照组相比无影响。
  • 225Ac-DOTA-daratumumab呈剂量依赖性效应,0.925、1.85和3.7 kBq分别将生存期较未治疗对照组(35天)延长至47、52和73天,所有3个剂量均显著延迟肿瘤生长。
  • 225Ac更高剂量11.1和22.2 kBq导致生存期等效延长至82天,但伴有显著全身毒性。

关键数值与推荐

  • 177Lu-DOTA-daratumumab剂量-反应:1.85 MBq延长生存至47天;3.7 MBq至55天;7.4 MBq至58天;11.1 MBq根除肿瘤但无生存获益。
  • 225Ac-DOTA-daratumumab剂量-反应:0.925 kBq延长生存至47天;1.85 kBq至52天;3.7 kBq至73天;11.1和22.2 kBq生存期等效至82天伴显著全身毒性。
  • 未治疗对照组生存期为35天。

临床怎么用

  • 临床前数据提示CD38靶向α放射免疫治疗(225Ac标记)可能较β治疗(177Lu标记)在延迟肿瘤生长和降低全身毒性方面更具优势,值得进一步转化研究。

局限性

  • 本研究为临床前动物模型研究,结果外推到临床多发性骨髓瘤患者需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted therapies for multiple myeloma (MM) include the anti-CD38 antibody daratumumab, which, in addition to its inherent cytotoxicity, can be radiolabeled with tracers for imaging and with β- and α-emitter radionuclides for radioimmunotherapy. Methods: We have compared the potential therapeutic efficacy of β- versus α-emitter radioimmunotherapy using radiolabeled DOTA-daratumumab in a preclinical model of disseminated multiple myeloma. Multiple dose levels were investigated to find the dose with the highest efficacy and lowest toxicity. Results: In a dose–response study with the β-emitter 177Lu-DOTA-daratumumab, the lowest tested dose, 1.85 MBq, extended survival from 37 to 47 d but did not delay tumor growth. Doses of 3.7 and 7.4 MBq extended survival to 55 and 58 d, respectively, causing a small equivalent delay in tumor growth, followed by regrowth. The higher dose, 11.1 MBq, eradicated the tumor but had no effect on survival compared with untreated controls, because of whole-body toxicity. In contrast, the α-emitter 225Ac-DOTA-daratumumab had a dose-dependent effect, in which 0.925, 1.85, and 3.7 kBq increased survival, compared with untreated controls (35 d), to 47, 52, and 73 d, respectively, with a significant delay in tumor growth for all 3 doses. Higher doses of 11.1 and 22.2 kBq resulted in equivalent survival to 82 d but with significant whole-body toxicity. Parallel studies with untargeted 225Ac-DOTA-trastuzumab conferred no improvement over untreated controls and resulted in whole-body toxicity. Conclusion: We conclude, and mathematic modeling confirms, that maximal biologic doses were achieved by targeted α-therapy and demonstrated 225Ac to be superior to 177Lu in delaying tumor growth and decreasing whole-body toxicity.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Minnix M, Adhikarla V, Caserta E, et al. Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model. J Nucl Med. 2020. PMID: 33127621. doi:10.2967/jnumed.120.251983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。